Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CR103995 Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma III Hormonal Therapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor bortezomib; dexamethasone; daratumumab
BMT-CTN 1304 A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age III Bone Marrow Transplant / Stem Cell Transplant, Hormonal Therapy, Signal Transduction Inhibitor, Immunomodulatory Agent bortezomib; dexamethasone; lenalidomide
CR100755 A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma II Immunotherapy (Monoclonal Antibody) siltuximab
UPCC-27412 A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function I / II Hormonal Therapy, Immunomodulatory Agent dexamethasone; lenalidomide
UPCC-38413 Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects I / II Chemotherapy, Hormonal Therapy, Immunomodulatory Agent dexamethasone; pomalidomide; Oprozomib
AMyC 10-MM-01 A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma I / II Hormonal Therapy, Signal Transduction Inhibitor, Immunomodulatory Agent dexamethasone; carfilzomib; pomalidomide
ACY-100 A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma I / II Hormonal Therapy, Signal Transduction Inhibitor bortezomib; dexamethasone; Rocilinostat
UPCC 12414 A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA I Immunotherapy
UPCC-31414 An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma I Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor, Immunomodulatory Agent bortezomib; melphalan; thalidomide; prednisone; dexamethasone; Acetaminophen; pomalidomide; daratumumab; diphenhydramine
UPCC 02413 Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT I Immunotherapy anti-CD19-CAR vector-transduced T cells
UPCC 16414 A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma I Immunotherapy Elotuzumab; BMS-986015; urelumab
UPCC 39413 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma I Signal Transduction Inhibitor
UPCC-03714 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies I Signal Transduction Inhibitor
UPCC 14413 A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis I Hormonal Therapy, Signal Transduction Inhibitor dexamethasone; carfilzomib
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC 1412 INSPIRE for Survivorship After Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-media Program for Long-term Hematopoietic Cell Transplantation Survivors III Supportive Care Not Applicable
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC 32413 A Phase I, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis I / II Immunotherapy (Monoclonal Antibody)
UPCC 08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
UPCC-05411 A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma 0 Blood or Tissue Collection Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
UPCC-28412 A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM) Not Specified Observational Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC 01614 A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor altiratinib
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.